Radiotherapy Trials
1. Cisplatin, Etoposide, and Two Different Schedules of Radiation Therapy in Treating Patients With Limited Stage Small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT00433563 |
This study is ongoing, but not recruiting participants
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer.
PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer
Ontario
Princess Margaret Hospital, Toronto
2. Individual Boosting in Non-Small Cell Lung Cancer Using Hypofraction, Intensity-modulated Radiation Therapy and Respiratory Gating
| ClinicalTrials.gov Identifier: |
NCT00690963 |
This study is ongoing, but not recruiting participants.
The purpose of this study is to determine whether the combination of custom designed intensity-modulated radiotherapy (based on individual tumor anatomy) with regular chepotherapy, will be safe enough to allow further intensification of radiation treatment.
Alberta
Cross Cancer Institute, Edmonton
3. Short Neoadjuvant Hemithoracic IMRT for MPM
| ClinicalTrials.gov Identifier: |
NCT00797719 |
A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma.
Ontario
University Health Network, Toronto
4. Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT01426841 |
This study is ongoing, but not recruiting participants.
This study is intended to assess the feasibility of adjusting a radiation plan during its course to accommodate for a shrinking tumour target. The investigators hypothesize that an adaptive radiotherapy (RT) planning strategy for small cell lung cancer (SCLC) patients with chest-confined disease will allow for safe delivery of higher doses of chest RT than a non-adaptive RT planning approach without subjecting normal critical structures to unacceptable doses of radiotherapy.
Alberta
Cross Cancer Institute
5. Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients (LUSTRE)
| ClinicalTrials.gov Identifier: |
NCT01968941 |
A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy.
Ontario
Juravinski Hospital Cancer Center, Hamilton
Niagara Health System-Walker Family Cancer Centre
St. Catharines, Ontario
British Columbia
BCCA Vancouver Island Cancer Centre
Victoria, British Columbia
Alberta
Tom Baker Cancer Centre
Calgary
Manitoba
Cancer Care Manitoba
Winnipeg, Manitoba
Quebec
CHUM Hospital Notre Dame
Montreal, Quebec
Hôpital Maisonneuve-Rosemont
Montreal, Quebec
Montreal General Hospital McGill
Montreal, Quebec
Saskatchewan
Saskatoon Cancer Centre
Saskatoon, Saskatchewan
6. Stereotactic Radiotherapy (SBRT) of Lung Metastasis
| ClinicalTrials.gov Identifier: |
NCT01803542 |
The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up.
Ontario
Princess Margaret Hospital, University Health Network
Toronto
7. Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
| ClinicalTrials.gov Identifier: |
NCT01279408 |
The aim of the study is to assess current practice within PROP &lung teams, for treating asymptomatic patients with centrally located non-small cell lung cancer (NSCLC), and to observe outcomes for those patients receiving immediate or deferred RT. This is a prospective cohort trial. Patients will be managed by immediate radiotherapy (RT) or a deferred approach according to physicians' individual current clinical practice.
Ontario
University Health Network
Toronto
8. Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
| ClinicalTrials.gov Identifier: |
NCT02002052 |
Functional lung avoidance radiotherapy aims to reduce radiotherapy dose to regions of functioning lung, instead depositing dose in areas of lung that are not well-ventilated.
Ontario
London Health Sciences Center
London
9. A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT02136355 |
Stereotactic ablative radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment.
The study combines SABR and surgery to treat non-small cell lung cancer. SABR will be done first, with surgery done approximately 10 weeks later. There will be some extra imaging done before and after the SABR.
The purpose of this study is to determine how effective SABR is in killing the cancer cells, and if SABR can help make surgery more effective.
Ontario
London Regional Cancer Program of the Lawson Health Research Institute
10. Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (LINNEARRE-I)
| ClinicalTrials.gov Identifier: |
NCT02433574 |
This is a phase I study that investigates the feasibility and safety of delivering Stereotactic Body Radiotherapy (SBRT) to patients with locally invasive NSCLC (cT3-4, N0-1) who are at risk for incomplete resection.
Twenty patients with NSCLC will be treated with SBRT followed by surgery and appropriate adjuvant therapy. Patients will be divided into groups, of 5 patients each, treated with escalating doses (35, 40, 45 and 50 Gy) in 10 daily fractions.
The primary outcome is the feasibility i.e. the ability to complete safely SBRT and surgery (within 6 weeks). Secondary outcomes include acute and late adverse events, R0/R1/R2 rates and secondary surrogates of feasibility. If successful, this study will lead to further evaluation of pre-operative SBRT in NSCLC.
Ontario
Juravinski Cancer Center
Hamilton
11. Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT01480973 |
SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately describe, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
Ontario
University Health Network, Toronto
12. Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC)
| ClinicalTrials.gov Identifier: |
NCT02756793 |
A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive non-small cell lung cancer. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions. Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).
British Columbia
BC Cancer Agency Fraser Valley
Surrey, V3V 1Z2
Ontario
London Regional Cancer Program
London, Ontario, N6A 4L6
13. Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy (PET-BOOST)
| ClinicalTrials.gov Identifier: |
NCT02788461 |
A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost. All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan within two weeks prior to starting treatment. The primary outcome is to determine if dose escalation to metabolically active tumour subvolumes will reduce local-regional failure rate at 2 years.
Ontario
London Regional Cancer Program
London, N6A 4L6
Princess Margaret Cancer Centre
Toronto, M5G 2M9
14. Phase II Trial of Individualized Lung Tumour Stereotactic Ablative Radiotherapy (iSABR)
| ClinicalTrials.gov Identifier: |
NCT01463423 |
A research study using a method of treating lug cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumours with SABR based on tumour-specific factors.
Ontario
Princess Margaret Cancer Center
15. Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
| ClinicalTrials.gov Identifier: |
NCT02635009 |
This randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (limited stage) or has spread outside of the lung in which it began or to other parts of the body (extensive stage). Radiation therapy uses high energy x-rays to kill tumour cells and shrink tumours. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It is not yet known whether giving whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Quebec
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Quebec City, G1R 2J6
16. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) forLung Cancer (STABLE-MATES)
| ClinicalTrials.gov Identifier: |
NCT02468024 |
JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial.
Quebec
CHUM
Montréal, Quebec, 26214
17. Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
| ClinicalTrials.gov Identifier: |
NCT02973789 |
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Quebec
McGill University Health Centre Recruiting
Montréal, Quebec, Canada, H4A 3J1
Contact: Nicola Raby, 514-934-1934 ext. 34095
nicola.raby@muhc.mcgill.ca
Principal Investigator: Scott Owen, MD
Centre intégré universitaire de santé et de services sociaux de l'Estrie –
Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS) Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Anick Champoux, RN
819-346-1110 ext. 12811
anick.champoux.ciussse-chus@ssss.gouv.qc.ca
Principal Investigator: Nicole Bouchard, MD
Saskatchewan
Allan Blair Cancer Center Recruiting
Regina, Saskatchewan, Canada, S4T 7T1
Contact: Wendie Templeton, CCRP
306-766-2488
wendie.templeton@saskcancer.ca
Principal Investigator: Mussawar Iqbal, MD